Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

IMM. Lakeman, AJ. van den Broek, JAM. Vos, DR. Barnes, J. Adlard, IL. Andrulis, A. Arason, N. Arnold, BK. Arun, J. Balmaña, D. Barrowdale, J. Benitez, A. Borg, T. Caldés, MA. Caligo, WK. Chung, KBM. Claes, GEMO Study Collaborators, EMBRACE...

. 2021 ; 23 (9) : 1726-1737. [pub] 20210610

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003812

Grantová podpora
UL1 TR000124 NCATS NIH HHS - United States
R01 CA214545 NCI NIH HHS - United States
C1287/A16563 Cancer Research UK - United Kingdom
P30 CA168524 NCI NIH HHS - United States
C5047/A10692 Cancer Research UK - United Kingdom
A11174 Cancer Research UK - United Kingdom
C5047/A8384 Cancer Research UK - United Kingdom
P30 CA008748 NCI NIH HHS - United States
U19 CA148065 NCI NIH HHS - United States
P20 GM130423 NIGMS NIH HHS - United States
RC4 CA153828 NCI NIH HHS - United States
C1281/A12014 Cancer Research UK - United Kingdom
C12292/A2086 Cancer Research UK - United Kingdom
C12292/A11174 Cancer Research UK - United Kingdom
Department of Health - United Kingdom
C1287/A 10710 Cancer Research UK - United Kingdom
CIHR - Canada
U10 CA180822 NCI NIH HHS - United States
C5047/A15007 Cancer Research UK - United Kingdom
UM1 CA164920 NCI NIH HHS - United States
U10 CA180868 NCI NIH HHS - United States
UL1 TR001881 NCATS NIH HHS - United States
C8197/A16565 Cancer Research UK - United Kingdom
C1287/A10118 Cancer Research UK - United Kingdom
R25 CA112486 NCI NIH HHS - United States

PURPOSE: To evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes. METHODS: We included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk. RESULTS: For BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06-1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07-1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC < age 40 years, the cumulative PRS313 5th and 95th percentile 10-year CBC risks were 22% and 32% for BRCA1 and 13% and 23% for BRCA2 heterozygotes, respectively. CONCLUSION: The PRS313 can be used to refine individual CBC risks for BRCA1/2 heterozygotes of European ancestry, however the PRS313 needs to be considered in the context of a multifactorial risk model to evaluate whether it might influence clinical decision-making.

Basser Center for BRCA Abramson Cancer Center University of Pennsylvania Philadelphia PA USA

Biomedical Sciences Institute University of Porto Porto Portugal

BMC Faculty of Medicine University of Iceland Reykjavik Iceland

Breast Cancer Research Programme Cancer Research Malaysia Subang Jaya Selangor Malaysia

Cancer Genetics and Prevention Program University of California San Francisco San Francisco CA USA

Cancer Genetics Service National Cancer Centre Singapore Singapore

Cancer Research Institute Seoul National University Seoul Korea

Cancer Risk and Prevention Clinic Dana Farber Cancer Institute Boston MA USA

Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core Cedars Sinai Medical Center Los Angeles CA USA

Center for Clinical Cancer Genetics The University of Chicago Chicago IL USA

Center for Familial Breast and Ovarian Cancer Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

Center for Integrated Oncology Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

Center for Medical Genetics NorthShore University HealthSystem Evanston IL USA

Center for Molecular Medicine Cologne Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany

Centre for Cancer Genetic Epidemiology Department of Oncology University of Cambridge Cambridge UK

Centre for Cancer Genetic Epidemiology Department of Public Health and Primary Care University of Cambridge Cambridge UK

Centre for Epidemiology and Biostatistics Melbourne School of Population and Global Health The University of Melbourne Melbourne VIC Australia

Centre for Medical Genetics Ghent University Ghent Belgium

Centro de Investigación en Red de Enfermedades Raras Madrid Spain

Chronic Disease Epidemiology Yale School of Public Health New Haven CT USA

Clalit National Cancer Control Center Carmel Medical Center and Technion Faculty of Medicine Haifa Israel

Clinical Genetics Branch Division of Cancer Epidemiology and Genetics National Cancer Institute Bethesda MD USA

Clinical Genetics Guy's and St Thomas' NHS Foundation Trust London UK

Clinical Genetics Karolinska Institutet Stockholm Sweden

Clinical Genetics Research Lab Department of Cancer Biology and Genetics Memorial Sloan Kettering Cancer Center New York NY USA

Clinical Genetics Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA

David Geffen School of Medicine Department of Obstetrics and Gynecology University of California at Los Angeles Los Angeles CA USA

Département de Génétique CHU de Grenoble Grenoble France

Department of Biomedical Sciences Seoul National University Graduate School Seoul Korea

Department of Breast Medical Oncology University of Texas MD Anderson Cancer Center Houston TX USA

Department of Cancer Biology and Genetics The Ohio State University Columbus OH USA

Department of Cancer Epidemiology and Genetics Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Clinical Genetics Aarhus University Hospital Aarhus Denmark

Department of Clinical Genetics Erasmus University Medical Center CA Rotterdam The Netherlands

Department of Clinical Genetics Fox Chase Cancer Center Philadelphia PA USA

Department of Clinical Genetics Leiden University Medical Center Leiden The Netherlands

Department of Clinical Genetics Odense University Hospital Odence C Denmark

Department of Clinical Genetics Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

Department of Dermatology Huntsman Cancer Institute University of Utah School of Medicine Salt Lake City UT USA

Department of Epidemiology and Biostatistics Memorial Sloan Kettering Cancer Center New York NY USA

Department of Epidemiology and Population Health Stanford University School of Medicine Stanford CA USA

Department of Genetics and Computational Biology QIMR Berghofer Medical Research Institute Brisbane QLD Australia

Department of Genetics and Pathology Pomeranian Medical University Szczecin Poland

Department of Genetics Portuguese Oncology Institute Porto Portugal

Department of Genetics University of Pretoria Arcadia South Africa

Department of Gynaecology and Obstetrics University Hospital of Schleswig Holstein Campus Kiel Christian Albrechts University Kiel Kiel Germany

Department of Human Genetics Leiden University Medical Center Leiden The Netherlands

Department of Internal Medicine Division of Medical Oncology University of Kansas Medical Center Westwood KS USA

Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

Department of Medical Genetics National Institute for Health Research Cambridge Biomedical Research Centre University of Cambridge Vol Box 134 Level 6 Addenbrooke's Treatment Centre Addenbrooke's Hosptital Cambridge UK

Department of Medical Oncology Beth Israel Deaconess Medical Center Boston MA USA

Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam The Netherlands

Department of Medical Oncology Vall d'Hebron Barcelona Hospital Campus University Hospital of Vall d'Hebron Barcelona Spain

Department of Medicine Division of Oncology Stanford Cancer Institute Stanford University School of Medicine Stanford CA USA

Department of Medicine Magee Womens Hospital University of Pittsburgh School of Medicine Pittsburgh PA USA

Department of Molecular Genetics National Institute of Oncology Budapest Hungary

Department of Molecular Genetics University of Toronto Toronto ON Canada

Department of Obstetrics and Gynecology Helsinki University Hospital University of Helsinki Helsinki Finland

Department of Oncology Lund University and Skåne University Hospital Lund Sweden

Department of Pathology and Laboratory Medicine University of Kansas Medical Center Kansas City KS USA

Department of Pathology Landspitali University Hospital Reykjavik Iceland

Department of Pathology Leiden University Medical Center Leiden The Netherlands

Department of Population Sciences Beckman Research Institute of City of Hope Duarte CA USA

Department of Preventive Medicine Seoul National University College of Medicine Seoul Korea

Department of Surgery Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

Department of Surgery Hong Kong Sanatorium and Hospital Happy Valley Hong Kong

Department of Surgery The University of Hong Kong Pok Fu Lam Hong Kong

Department of Tumour Biology INSERM U830 Paris France

Departments of Pediatrics and Medicine Columbia University New York NY USA

Dept of OB GYN and Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Dept of OB GYN Medical University of Vienna Vienna Austria

Division of Evolution and Genomic Sciences School of Biological Sciences Faculty of Biology Medicine and Health University of Manchester Manchester Academic Health Science Centre Manchester UK

Division of Molecular Pathology The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands

Division of Psychosocial Research and Epidemiology The Netherlands Cancer Institute Antoni van Leeuwenhoek hospital Amsterdam The Netherlands

Family Cancer Clinic The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands

Fred A Litwin Center for Cancer Genetics Lunenfeld Tanenbaum Research Institute of Mount Sinai Hospital Toronto ON Canada

Fundación Pública Galega de Medicina Xenómica Santiago de Compostela Spain

Genetic Epidemiology of Cancer team Paris France

Genome Diagnostics Program IFOM the FIRC Institute of Molecular Oncology Milan Italy

Genomics Center Centre Hospitalier Universitaire de Québec Université Laval Research Center Québec City QC Canada

Hematology Oncology and Transfusion Medicine Center Department of Molecular and Regenerative Medicine Vilnius University Hospital Santariskiu Clinics Vilnius Lithuania

Hereditary cancer Genetics Group Vall d'Hebron Institute of Oncology Barcelona Spain

Hereditary Cancer Program ONCOBELL IDIBELL IGTP Catalan Institute of Oncology CIBERONC Barcelona Spain

Hong Kong Hereditary Breast Cancer Family Registry Cancer Genetics Centre Happy Valley Hong Kong

Human Cancer Genetics Programme Spanish National Cancer Research Centre Madrid Spain

Immunology and Molecular Oncology Unit Veneto Institute of Oncology IOV IRCCS Padua Italy

Independent Laboratory of Molecular Biology and Genetic Diagnostics Pomeranian Medical University Szczecin Poland

Institut Curie Paris France

Institute for Medical Informatics Statistics and Epidemiology University of Leipzig Leipzig Germany

Institute of Clinical Molecular Biology University Hospital of Schleswig Holstein Campus Kiel Christian Albrechts University Kiel Kiel Germany

Institute of Human Genetics University Hospital Heidelberg Heidelberg Germany

Instituto de Investigación Sanitaria de Santiago de Compostela Complejo Hospitalario Universitario de Santiago SERGAS Santiago de Compostela Spain

Lee Kong Chian School of Medicine Nanyang Technological University Singapore Singapore

Lombardi Comprehensive Cancer Center Georgetown University Washington DC USA

Mines ParisTech Fontainebleau France

Molecular Diagnostics Laboratory INRASTES National Centre for Scientific Research 'Demokritos' Athens Greece

Molecular Genetics of Breast Cancer German Cancer Research Center Heidelberg Germany

Molecular Oncology Laboratory CIBERONC Hospital Clinico San Carlos IdISSC Madrid Spain

N N Petrov Institute of Oncology St Petersburg Russia

North West Genomics Laboratory Hub Manchester Centre for Genomic Medicine St Mary's Hospital Manchester University NHS Foundation Trust Manchester Academic Health Science Centre Manchester UK

NRG Oncology Statistics and Data Management Center Roswell Park Cancer Institute Buffalo NY USA

Oncogenetics Team The Institute of Cancer Research and Royal Marsden NHS Foundation Trust London UK

Parkville Familial Cancer Centre Peter MacCallum Cancer Center Melbourne VIC Australia

Program in Cancer Genetics Departments of Human Genetics and Oncology McGill University Montréal QC Canada

Sackler Faculty of Medicine Tel Aviv University Ramat Aviv Israel

Schools of Medicine and Public Health Division of Cancer Prevention and Control Research Jonsson Comprehensive Cancer Centre UCLA Los Angeles CA USA

Service de Biologie de la reproduction Cytogénétique et Génétique Médicale CHI Poissy Saint Germain Poissy France

Service de Génétique Institut Curie Paris France

Sir Peter MacCallum Department of Oncology The University of Melbourne Melbourne VIC Australia

SOD Genetica Molecolare University Hospital Pisa Italy

State Research Institute Centre for Innovative Medicine Vilnius Lithuania

The Susanne Levy Gertner Oncogenetics Unit Chaim Sheba Medical Center Ramat Gan Israel

The University of Chicago Pritzker School of Medicine Chicago IL USA

Unit of Medical Genetics Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milan Italy

Unit of Molecular Bases of Genetic Risk and Genetic Testing Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Université Paris Descartes Paris France

Waukesha Memorial Hospital Pro Health Care Waukesha WI USA

Yorkshire Regional Genetics Service Chapel Allerton Hospital Leeds UK

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003812
003      
CZ-PrNML
005      
20220127145831.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41436-021-01198-7 $2 doi
035    __
$a (PubMed)34113011
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lakeman, Inge M M $u Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands $u Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
245    14
$a The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant / $c IMM. Lakeman, AJ. van den Broek, JAM. Vos, DR. Barnes, J. Adlard, IL. Andrulis, A. Arason, N. Arnold, BK. Arun, J. Balmaña, D. Barrowdale, J. Benitez, A. Borg, T. Caldés, MA. Caligo, WK. Chung, KBM. Claes, GEMO Study Collaborators, EMBRACE Collaborators, JM. Collée, FJ. Couch, MB. Daly, J. Dennis, M. Dhawan, SM. Domchek, R. Eeles, C. Engel, DG. Evans, L. Feliubadaló, L. Foretova, E. Friedman, D. Frost, PA. Ganz, J. Garber, SA. Gayther, AM. Gerdes, AK. Godwin, DE. Goldgar, E. Hahnen, CR. Hake, U. Hamann, FBL. Hogervorst, MJ. Hooning, JL. Hopper, PJ. Hulick, EN. Imyanitov, OCGN Investigators, HEBON Investigators, KconFab Investigators, C. Isaacs, L. Izatt, A. Jakubowska, PA. James, R. Janavicius, UB. Jensen, Y. Jiao, EM. John, V. Joseph, BY. Karlan, CM. Kets, I. Konstantopoulou, A. Kwong, C. Legrand, G. Leslie, F. Lesueur, JT. Loud, J. Lubiński, S. Manoukian, L. McGuffog, A. Miller, DM. Gomes, M. Montagna, E. Mouret-Fourme, KL. Nathanson, SL. Neuhausen, H. Nevanlinna, JNY. Yie, E. Olah, OI. Olopade, SK. Park, MT. Parsons, P. Peterlongo, M. Piedmonte, P. Radice, J. Rantala, G. Rennert, HA. Risch, RK. Schmutzler, P. Sharma, J. Simard, CF. Singer, Z. Stadler, D. Stoppa-Lyonnet, C. Sutter, YY. Tan, MR. Teixeira, SH. Teo, A. Teulé, M. Thomassen, DL. Thull, M. Tischkowitz, AE. Toland, N. Tung, EJ. van Rensburg, A. Vega, B. Wappenschmidt, P. Devilee, CJ. van Asperen, JL. Bernstein, K. Offit, DF. Easton, MA. Rookus, G. Chenevix-Trench, AC. Antoniou, M. Robson, MK. Schmidt
520    9_
$a PURPOSE: To evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes. METHODS: We included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk. RESULTS: For BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06-1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07-1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC < age 40 years, the cumulative PRS313 5th and 95th percentile 10-year CBC risks were 22% and 32% for BRCA1 and 13% and 23% for BRCA2 heterozygotes, respectively. CONCLUSION: The PRS313 can be used to refine individual CBC risks for BRCA1/2 heterozygotes of European ancestry, however the PRS313 needs to be considered in the context of a multifactorial risk model to evaluate whether it might influence clinical decision-making.
650    _2
$a dospělí $7 D000328
650    _2
$a protein BRCA1 $x genetika $7 D019313
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    12
$a nádory prsu $x diagnóza $x epidemiologie $x genetika $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a heterozygot $7 D006579
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a van den Broek, Alexandra J $u Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
700    1_
$a Vos, Juliën A M $u Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
700    1_
$a Barnes, Daniel R $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
700    1_
$a Adlard, Julian $u Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK
700    1_
$a Andrulis, Irene L $u Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada $u Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
700    1_
$a Arason, Adalgeir $u Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland $u BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland
700    1_
$a Arnold, Norbert $u Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany $u Institute of Clinical Molecular Biology, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany
700    1_
$a Arun, Banu K $u Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
700    1_
$a Balmaña, Judith $u Hereditary cancer Genetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain $u Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, University Hospital of Vall d'Hebron, Barcelona, Spain
700    1_
$a Barrowdale, Daniel $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
700    1_
$a Benitez, Javier $u Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain $u Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
700    1_
$a Borg, Ake $u Department of Oncology, Lund University and Skåne University Hospital, Lund, Sweden
700    1_
$a Caldés, Trinidad $u Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain
700    1_
$a Caligo, Maria A $u SOD Genetica Molecolare. University Hospital, Pisa, Italy
700    1_
$a Chung, Wendy K $u Departments of Pediatrics and Medicine, Columbia University, New York, NY, USA
700    1_
$a Claes, Kathleen B M $u Centre for Medical Genetics, Ghent University, Ghent, Belgium
700    1_
$a Collée, J Margriet $u Department of Clinical Genetics, Erasmus University Medical Center, CA, Rotterdam, The Netherlands
700    1_
$a Couch, Fergus J $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Daly, Mary B $u Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA
700    1_
$a Dennis, Joe $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
700    1_
$a Dhawan, Mallika $u Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, CA, USA
700    1_
$a Domchek, Susan M $u Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Eeles, Ros $u Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK
700    1_
$a Engel, Christoph $u Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
700    1_
$a Evans, D Gareth $u Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK $u North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
700    1_
$a Feliubadaló, Lidia $u Hereditary Cancer Program, ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Barcelona, Spain
700    1_
$a Foretova, Lenka $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Friedman, Eitan $u The Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Ramat Gan, Israel $u Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
700    1_
$a Frost, Debra $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
700    1_
$a Ganz, Patricia A $u Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Centre, UCLA, Los Angeles, CA, USA
700    1_
$a Garber, Judy $u Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, MA, USA
700    1_
$a Gayther, Simon A $u Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core. Cedars-Sinai Medical Center, Los Angeles, CA, USA
700    1_
$a Gerdes, Anne-Marie $u Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Godwin, Andrew K $u Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA
700    1_
$a Goldgar, David E $u Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA
700    1_
$a Hahnen, Eric $u Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany $u Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
700    1_
$a Hake, Christopher R $u Waukesha Memorial Hospital-Pro Health Care, Waukesha, WI, USA
700    1_
$a Hamann, Ute $u Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
700    1_
$a Hogervorst, Frans B L $u Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
700    1_
$a Hooning, Maartje J $u Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
700    1_
$a Hopper, John L $u Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia
700    1_
$a Hulick, Peter J $u Center for Medical Genetics, NorthShore University HealthSystem, Evanston, IL, USA $u The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
700    1_
$a Imyanitov, Evgeny N $u N.N. Petrov Institute of Oncology, St. Petersburg, Russia
700    1_
$a Isaacs, Claudine $u Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
700    1_
$a Izatt, Louise $u Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK
700    1_
$a Jakubowska, Anna $u Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland $u Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland
700    1_
$a James, Paul A $u Parkville Familial Cancer Centre, Peter MacCallum Cancer Center, Melbourne, VIC, Australia $u Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
700    1_
$a Janavicius, Ramunas $u Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania $u State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
700    1_
$a Jensen, Uffe Birk $u Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark
700    1_
$a Jiao, Yue $u Genetic Epidemiology of Cancer team, Paris, France $u Institut Curie, Paris, France $u Mines ParisTech, Fontainebleau, France
700    1_
$a John, Esther M $u Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA $u Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
700    1_
$a Joseph, Vijai $u Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Karlan, Beth Y $u David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, CA, USA
700    1_
$a Kets, Carolien M $u Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
700    1_
$a Konstantopoulou, Irene $u Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research 'Demokritos', Athens, Greece
700    1_
$a Kwong, Ava $u Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Centre, Happy Valley, Hong Kong $u Department of Surgery, The University of Hong Kong, Pok Fu Lam, Hong Kong $u Department of Surgery, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
700    1_
$a Legrand, Clémentine $u Département de Génétique, CHU de Grenoble, Grenoble, France
700    1_
$a Leslie, Goska $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
700    1_
$a Lesueur, Fabienne $u Genetic Epidemiology of Cancer team, Paris, France $u Institut Curie, Paris, France $u Mines ParisTech, Fontainebleau, France
700    1_
$a Loud, Jennifer T $u Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
700    1_
$a Lubiński, Jan $u Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
700    1_
$a Manoukian, Siranoush $u Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
700    1_
$a McGuffog, Lesley $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
700    1_
$a Miller, Austin $u NRG Oncology, Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY, USA
700    1_
$a Gomes, Denise Molina $u Service de Biologie de la reproduction, Cytogénétique et Génétique Médicale, CHI Poissy-Saint Germain, Poissy, France
700    1_
$a Montagna, Marco $u Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
700    1_
$a Mouret-Fourme, Emmanuelle $u Service de Génétique, Institut Curie, Paris, France
700    1_
$a Nathanson, Katherine L $u Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Neuhausen, Susan L $u Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA
700    1_
$a Nevanlinna, Heli $u Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
700    1_
$a Yie, Joanne Ngeow Yuen $u Cancer Genetics Service, National Cancer Centre, Singapore, Singapore $u Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
700    1_
$a Olah, Edith $u Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary
700    1_
$a Olopade, Olufunmilayo I $u Center for Clinical Cancer Genetics, The University of Chicago, Chicago, IL, USA
700    1_
$a Park, Sue K $u Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea $u Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea $u Cancer Research Institute, Seoul National University, Seoul, Korea
700    1_
$a Parsons, Michael T $u Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
700    1_
$a Peterlongo, Paolo $u Genome Diagnostics Program, IFOM-the FIRC Institute of Molecular Oncology, Milan, Italy
700    1_
$a Piedmonte, Marion $u NRG Oncology, Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo, NY, USA
700    1_
$a Radice, Paolo $u Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy
700    1_
$a Rantala, Johanna $u Clinical Genetics, Karolinska Institutet, Stockholm, Sweden
700    1_
$a Rennert, Gad $u Clalit National Cancer Control Center, Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel
700    1_
$a Risch, Harvey A $u Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA
700    1_
$a Schmutzler, Rita K $u Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany $u Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany $u Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
700    1_
$a Sharma, Priyanka $u Department of Internal Medicine, Division of Medical Oncology, University of Kansas Medical Center, Westwood, KS, USA
700    1_
$a Simard, Jacques $u Genomics Center, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, Québec City, QC, Canada
700    1_
$a Singer, Christian F $u Dept of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Stadler, Zsofia $u Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Stoppa-Lyonnet, Dominique $u Service de Génétique, Institut Curie, Paris, France $u Department of Tumour Biology, INSERM U830, Paris, France $u Université Paris Descartes, Paris, France
700    1_
$a Sutter, Christian $u Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
700    1_
$a Tan, Yen Yen $u Dept of OB/GYN, Medical University of Vienna, Vienna, Austria
700    1_
$a Teixeira, Manuel R $u Department of Genetics, Portuguese Oncology Institute, Porto, Portugal $u Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal
700    1_
$a Teo, Soo Hwang $u Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia $u Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
700    1_
$a Teulé, Alex $u Hereditary Cancer Program, ONCOBELL-IDIBELL-IGTP, Catalan Institute of Oncology, CIBERONC, Barcelona, Spain
700    1_
$a Thomassen, Mads $u Department of Clinical Genetics, Odense University Hospital, Odence C, Denmark
700    1_
$a Thull, Darcy L $u Department of Medicine, Magee-Womens Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
700    1_
$a Tischkowitz, Marc $u Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, QC, Canada $u Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge. Vol Box 134, Level 6 Addenbrooke's Treatment Centre, Addenbrooke's Hosptital, Cambridge, UK
700    1_
$a Toland, Amanda E $u Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, USA
700    1_
$a Tung, Nadine $u Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
700    1_
$a van Rensburg, Elizabeth J $u Department of Genetics, University of Pretoria, Arcadia, South Africa
700    1_
$a Vega, Ana $u Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain $u Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain $u Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain
700    1_
$a Wappenschmidt, Barbara $u Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany $u Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
700    1_
$a Devilee, Peter $u Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands $u Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a van Asperen, Christi J $u Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Bernstein, Jonine L $u Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
700    1_
$a Offit, Kenneth $u Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA $u Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Easton, Douglas F $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK $u Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
700    1_
$a Rookus, Matti A $u Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands
700    1_
$a Chenevix-Trench, Georgia $u Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
700    1_
$a Antoniou, Antonis C $u Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
700    1_
$a Robson, Mark $u Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
700    1_
$a Schmidt, Marjanka K $u Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. mk.schmidt@nki.nl $u Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. mk.schmidt@nki.nl $u Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands. mk.schmidt@nki.nl
710    2_
$a GEMO Study Collaborators
710    2_
$a EMBRACE Collaborators
710    2_
$a OCGN Investigators
710    2_
$a HEBON Investigators
710    2_
$a KconFab Investigators
773    0_
$w MED00186213 $t Genetics in medicine : official journal of the American College of Medical Genetics $x 1530-0366 $g Roč. 23, č. 9 (2021), s. 1726-1737
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34113011 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145827 $b ABA008
999    __
$a ok $b bmc $g 1751317 $s 1154961
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 9 $d 1726-1737 $e 20210610 $i 1530-0366 $m Genetics in medicine $n Genet Med $x MED00186213
GRA    __
$a UL1 TR000124 $p NCATS NIH HHS $2 United States
GRA    __
$a R01 CA214545 $p NCI NIH HHS $2 United States
GRA    __
$a C1287/A16563 $p Cancer Research UK $2 United Kingdom
GRA    __
$a P30 CA168524 $p NCI NIH HHS $2 United States
GRA    __
$a C5047/A10692 $p Cancer Research UK $2 United Kingdom
GRA    __
$a A11174 $p Cancer Research UK $2 United Kingdom
GRA    __
$a C5047/A8384 $p Cancer Research UK $2 United Kingdom
GRA    __
$a P30 CA008748 $p NCI NIH HHS $2 United States
GRA    __
$a U19 CA148065 $p NCI NIH HHS $2 United States
GRA    __
$a P20 GM130423 $p NIGMS NIH HHS $2 United States
GRA    __
$a RC4 CA153828 $p NCI NIH HHS $2 United States
GRA    __
$a C1281/A12014 $p Cancer Research UK $2 United Kingdom
GRA    __
$a C12292/A2086 $p Cancer Research UK $2 United Kingdom
GRA    __
$a C12292/A11174 $p Cancer Research UK $2 United Kingdom
GRA    __
$p Department of Health $2 United Kingdom
GRA    __
$a C1287/A 10710 $p Cancer Research UK $2 United Kingdom
GRA    __
$p CIHR $2 Canada
GRA    __
$a U10 CA180822 $p NCI NIH HHS $2 United States
GRA    __
$a C5047/A15007 $p Cancer Research UK $2 United Kingdom
GRA    __
$a UM1 CA164920 $p NCI NIH HHS $2 United States
GRA    __
$a U10 CA180868 $p NCI NIH HHS $2 United States
GRA    __
$a UL1 TR001881 $p NCATS NIH HHS $2 United States
GRA    __
$a C8197/A16565 $p Cancer Research UK $2 United Kingdom
GRA    __
$a C1287/A10118 $p Cancer Research UK $2 United Kingdom
GRA    __
$a R25 CA112486 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...